Please provide your email address to receive an email when new articles are posted on . Patients with focal nonmotor seizures experienced a delay from first seizure to diagnosis that was 10 times ...

Please provide your email address to receive an email when new articles are posted on . “Elderly patients represent the most rapidly growing cohort of the epilepsy population,” Rohit Marawar, MD, ...

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

More than 3.4 million people in the United States have epilepsy, so it is a relatively common diagnosis. In fact, it is the fourth-most common neurologic condition in the world. November is National ...

Adding the novel drug XEN1101 to current antiseizure regimens significantly decreases seizures in patients with treatment-resistant focal epilepsy and can safely be taken at its highest dose, results ...

Rapport Therapeutics, Inc. (RAPP) on Monday said that a mid-stage clinical trial of RAP-219 in patients with drug-resistant focal onset seizures demonstrated a statistically significant reduction in ...

Patients with focal nonmotor seizures experience a "disproportionate delay to diagnosis" compared with those with focal motor seizures, especially among teens, new research suggests. Retrospective ...

Xenon (XENE) is in the process of nearly completing its phase 3 X-TOLE2 trial using its Kv7 potassium channel opener azetukalner for the treatment of patients with focal onset seizures [FOS]. As a ...

“It’s all about the brain,” said Jennifer DeWolfe, D.O., professor in the UAB Department of Neurology. “Seizure manifestations are stereotyped, so the same symptoms occur with each seizure that ...

PARIS--(BUSINESS WIRE)--On the occasion of World Epilepsy Day (14 th of February 2022), Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare ...